PTC Current Deferred Revenue from 2010 to 2026
| PTCT Stock | USD 69.45 1.25 1.77% |
Current Deferred Revenue | First Reported 2012-12-31 | Previous Quarter 9.8 M | Current Value 1.7 M | Quarterly Volatility 74.5 M |
Check PTC Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PTC Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 201.6 M, Total Revenue of 974.2 M or Research Development of 645.4 M, as well as many indicators such as Price To Sales Ratio of 4.7, Dividend Yield of 0.0 or Days Sales Outstanding of 52.14. PTC financial statements analysis is a perfect complement when working with PTC Therapeutics Valuation or Volatility modules.
PTC | Current Deferred Revenue | Build AI portfolio with PTC Stock |
The evolution of Current Deferred Revenue for PTC Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how PTC Therapeutics compares to historical norms and industry peers.
Latest PTC Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of PTC Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. PTC Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
PTC Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 22,021,114 | |
| Geometric Mean | 4,580,931 | |
| Coefficient Of Variation | 287.09 | |
| Mean Deviation | 28,894,054 | |
| Median | 4,151,000 | |
| Standard Deviation | 63,221,025 | |
| Sample Variance | 3996.9T | |
| Range | 265.6M | |
| R-Value | 0.09 | |
| Mean Square Error | 4225.9T | |
| R-Squared | 0.01 | |
| Significance | 0.72 | |
| Slope | 1,173,654 | |
| Total Sum of Squares | 63950.4T |
PTC Current Deferred Revenue History
About PTC Therapeutics Financial Statements
PTC Therapeutics shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although PTC Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in PTC Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on PTC Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 6.3 M | 6 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.